STTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Shattuck Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$5.37−0.05 (-0.92%)
Close on Oct 19, 2026
- Market cap
- $696.91M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-5150.8%−4779.0 pts over 5 years
Net margin
-4880.9%−4512.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -82.5% | +15.3% | -36.8% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -26.6% | -60.3% | |
| Return on assets | – | -18.6% | -53.6% | |
| Current ratio | – | 20.53 | 11.70 | |
| Capex to revenue | – | 7.3% | 7.1% | |
| Diluted shares | – | 16M | 70M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Shattuck Labs generated $333.24M from operations and spent $20.08M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$333.24M
Used
$20.08M
Capital expenditure$20.08M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4880.9%
×Asset turnover0.01×
×Equity multiplier1.12×
=Return on equity, FY2025-60.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4880.9% | 0.01× | 1.12× | -60.3% |
| FY2024 | -1318.1% | 0.05× | 1.12× | -67.2% |
| FY2023 | -5268.4% | 0.01× | 1.14× | -54.4% |
| FY2022 | -15635.7% | 0.00× | 1.12× | -45.5% |
| FY2021 | -149.8% | 0.09× | 1.11× | -15.5% |
| FY2020 | -368.5% | 0.05× | 1.43× | -26.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$48.81M
- Cash generatingOperating cash flow above zero-$39.88M
- Return on assets improvedROA up on the prior year-47.3% → -53.6%
- Earnings backed by cashOperating cash flow above net income-$39.88M vs -$48.81M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.88 → 11.70
- No dilutionShare count did not rise51M → 70M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.01